NO20063155L - Anti-IGF-I-reseptorantistoff - Google Patents

Anti-IGF-I-reseptorantistoff

Info

Publication number
NO20063155L
NO20063155L NO20063155A NO20063155A NO20063155L NO 20063155 L NO20063155 L NO 20063155L NO 20063155 A NO20063155 A NO 20063155A NO 20063155 A NO20063155 A NO 20063155A NO 20063155 L NO20063155 L NO 20063155L
Authority
NO
Norway
Prior art keywords
igf
antibodies
receptor
cancer
elevated level
Prior art date
Application number
NO20063155A
Other languages
English (en)
Norwegian (no)
Inventor
Rajeeva Singh
Daniel J Tavares
Nancy E Dagdigian
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of NO20063155L publication Critical patent/NO20063155L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
NO20063155A 2003-12-08 2006-07-07 Anti-IGF-I-reseptorantistoff NO20063155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody
PCT/US2004/038230 WO2005061541A1 (en) 2002-06-14 2004-12-07 Anti-igf-i receptor antibody

Publications (1)

Publication Number Publication Date
NO20063155L true NO20063155L (no) 2006-08-11

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063155A NO20063155L (no) 2003-12-08 2006-07-07 Anti-IGF-I-reseptorantistoff

Country Status (13)

Country Link
EP (1) EP1692176A4 (pt)
JP (1) JP2008502589A (pt)
KR (1) KR20070001883A (pt)
CN (1) CN1886424A (pt)
AU (1) AU2004303792A1 (pt)
BR (1) BRPI0417406A (pt)
CA (1) CA2548065A1 (pt)
CR (1) CR8426A (pt)
EA (1) EA009807B1 (pt)
EC (1) ECSP066595A (pt)
IL (1) IL174770A0 (pt)
MX (1) MXPA06005540A (pt)
NO (1) NO20063155L (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
CA2800311A1 (en) * 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CA3056573A1 (en) * 2017-05-30 2018-12-06 Teijin Pharma Limited Anti-igf-i receptor antibody
EP4678186A1 (en) * 2023-03-07 2026-01-14 Akeso Pharma Co., Ltd. Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143514A0 (en) * 1998-12-04 2002-04-21 Novartis Ag METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ3
NZ527302A (en) * 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
KR20050109489A (ko) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도

Also Published As

Publication number Publication date
JP2008502589A (ja) 2008-01-31
EP1692176A4 (en) 2008-11-12
AU2004303792A1 (en) 2005-07-07
EA200600931A1 (ru) 2006-10-27
EP1692176A1 (en) 2006-08-23
ECSP066595A (es) 2006-10-17
IL174770A0 (en) 2006-08-20
KR20070001883A (ko) 2007-01-04
EA009807B1 (ru) 2008-04-28
MXPA06005540A (es) 2006-08-17
CR8426A (es) 2007-12-04
CA2548065A1 (en) 2005-07-07
BRPI0417406A (pt) 2007-04-03
CN1886424A (zh) 2006-12-27

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
Ristau et al. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research
Wernicke et al. Prostate‐specific membrane antigen expression in tumor‐associated vasculature of breast cancers
Fong et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer
EA200970130A1 (ru) Антагонистическое антитело для лечения рака
Errarte et al. The expression of fibroblast activation protein in clear cell renal cell carcinomas is associated with synchronous lymph node metastases
ATE509033T1 (de) Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
Lastraioli et al. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma
Bai et al. The role of α-smooth muscle actin in confirming the microinvasion of laryngeal squamous cell carcinoma
WO2006099141A3 (en) Anti-mesothelin antibodies
BR112012021941A2 (pt) Proteínas terapêuticas de ligação a dll4
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2007149948A3 (en) Compositions and methods for diagnosis and treatment of tumors
JP2007504280A5 (pt)
Bernacki et al. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma
Fenton et al. Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
WO2005094348A3 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
EA200601405A1 (ru) Гуманизированное антитело
EP1539818A4 (en) COMPOSITIONS AND ITS USES FOR THE IDENTIFICATION AND TARGETTING OF PROVASOPRESSINEXPRIMATING CANCER CELLS
Xiao et al. Rapid diagnostic imaging and targeted immunotoxin delivery in aggressive prostate cancer using CEACAM5-specific nanobodies
EA200600931A1 (ru) Антитело против igf-i-рецептора
NO20004251L (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
Pawlikowski et al. Overexpression of prothymosin alpha is related to pituitary adenoma recurrence but not to adenoma invasiveness and proliferation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application